THA—A Review of the Literature and Its Use in Treatment of Five Overdose Patients

References

• Slovis T. L., Ott J. E., Teitelbaum D. T., Lipscomb W. Physostigmine therapy in acute tricyclic antidepressant poisoning. Clin. Toxicol. 1972; 4: 451
   Web of Science ®Google Scholar
• Bernards W. Case History H74: Reversal of phenothiazine coma with physostigmine. Anesth. Analg. 1973; 52: 938
   PubMed Web of Science ®Google Scholar
• Brown M. L., Gershon S., Lang W. J., Korol B. Effects of psychomimetric response to Ditran in dogs. Arch. Int. Pharmacodyn. 1966; 160: 407
   PubMedGoogle Scholar
• Burks J. S., Walker J. E., Rumack B. H., Ott J. E. Tricyclic antidepressant poisoning: Reversal of coma, choreoathetosis, and myoclonus by physostigmine. J. Am. Med. Assoc. 1974; 230: 1405
   PubMed Web of Science ®Google Scholar
• Coppolino C. A. Incidence of postanesthetic delirium in community hospital: A statistical study. Mil. Med. 1963; 28: 238
   Google Scholar
• Crowell E. B., Ketchum J. S. Treatment of scopolamine‐induced delirium by physostigmine. Clin. Pharmacol. Therap. 1967; 8: 409
   PubMed Web of Science ®Google Scholar
• El‐Yousef M. K., Janowsky D., Davis J. M., Senkenke H. J. Reversal of anti‐Parkinsonian drug toxicity by physostigmine. Am. J. Psychiatry 1973; 130: 141
   PubMed Web of Science ®Google Scholar
• Granacher R. P., Baldessarine R. Physostigmine‐Its use in acute anticholinergic syndrome with antidepressant and anti‐Parkinson drugs. Arch. Gen. Psychiatry 1975; 32: 375
   PubMed Web of Science ®Google Scholar
• Heiser J. F., Gillin J. C. The reversal of anticholinergic drug induced delirium and coma with physostigmine. Am. J. Psychiatry 1971; 127: 1050
   PubMed Web of Science ®Google Scholar
• Heiser J. F., Wilbert D. E. Reversal of delirium induced by tricyclic antidepressant drugs with physostigmine. Am. J. Psychiatry 1974; 131: 1275
   PubMed Web of Science ®Google Scholar
• Janowsky D. S., Davis J. M., El‐Yousef M. K., Senkenke H. J. Combined anticholinergic agents and atropine‐like delirium. Am. J. Psychiatry 1972; 129: 360
   PubMed Web of Science ®Google Scholar
• Newton R. W. Physostigmine salicylate in the treatment of tricyclic antidepressant overdose. J. Am. Med. Assoc. 1975; 231: 941
   PubMed Web of Science ®Google Scholar
• Rasmussen J. Poisoning by amitriptyline, imipramine, and nortriptyline. Dan. Med. Bull. 1966; 13: 201
   PubMed Web of Science ®Google Scholar
• Rumack B. H. Anticholinergic poisoning treatment with physostigmine. Pediatrics 1972; 53: 449
   Google Scholar
• Pharmacological Basis of Therapeutics5th ed., L. S. Goodman, A. Gilman. Macmillan, New York 1975
   Google Scholar
• Vance M. A., Ross S. M., Millington W. R., Blumberg J. B. Potentiation of tricyclic antidepressant toxicity by physostigmine in mice. Clin. Toxicol. 1977; 11: 413
   PubMed Web of Science ®Google Scholar
• Bell C., Gershon S., Carrol B., Holan G. Behavioral antagonism to a new psychomimetic: JB‐329. Arch. Int. Pharmacodyn. 1964; 147: 9
   PubMedGoogle Scholar
• Bell C., Gershon S. Experimental anticholinergic psychotomimetics: Antagonism of yohimbine and tecrine (THA). Med. Exp. 1964; 10: 15
   PubMedGoogle Scholar
• Gershon S., Newbauer H., Sundland D. M. Ditran and its antagonistics in a mixed psychiatric population. J. Nerv. Ment. Dis. 1966; 142: 265
   PubMed Web of Science ®Google Scholar
• Gershon S. Behavioral effects of anticholinergic psychotomimetics and their antagonists in man and animals. Rec. Adv. Biol. Psychi. 1966; 13: 141
   Google Scholar
• Itil T. M., Fink M. Anticholinergic drug induced delirium: Experimental modification, quantitative EEG, and behavioral correlation. J. Nerv. Ment. 1966; 143: 492
   PubMed Web of Science ®Google Scholar
• Itil T. M. Quantitative EEG changes induced by anticholinergic drugs and their behavioral correlates in man. Recent Adv. Biol. Psychiatry 1966; 13: 151
   Google Scholar
• Gershon S., Olaria J. J.B.‐329‐A new psychotomimetic, its antagonism by tetrahydro aminoacridine and its comparison with LSD, mescaline, and sernyl. J. Neuropsychiatry 1960; 1: 283
   PubMedGoogle Scholar
• Summers W. K. A clinical method for estimating risk of drug induced delirium. Life Sci. 1978; 22: 1511
   PubMed Web of Science ®Google Scholar
• Shaw F. H., Bentley G. Some aspects of the pharmacology of morphine with special reference to its antagonism by 5‐aminoacridine (THA) and other chemically related compounds. Med. J. Aust. 1949; 2: 868
   PubMed Web of Science ®Google Scholar
• Shaw F. H., Bentley G. A. Pharmacology of some new anticholinesterases. Aust. J. Exp. Biol. Med. Sci. 1953; 31: 573
   PubMedGoogle Scholar
• Shaw F. H., Schulman A. Treatment of intractable pain with large doses of morphine and diamine phenylthiazole. Br. Med. J. 1955; 1: 1367
   PubMed Web of Science ®Google Scholar
• Stone V., Moon W., Shaw F. H. Treatment of intractable pain with morphine and THA. Br. Med. J. 1961; 1: 471
   PubMed Web of Science ®Google Scholar
• Rees J. M. H. Anticurare activity of tacrine (THA). J. Pharm. Pharmacol. 1966; 18: 289
   PubMed Web of Science ®Google Scholar
• McCaul K., Robinson G. D. Suxamethonium extension by tetrahydroaminoacrine. Br. J. Anaest. 1967; 39: 629
   PubMedGoogle Scholar
• Ho A. K., Freeman S. E. Anticholinesterase activity by tetrahydroaminoacrine and succinylcholine hydrosis. Nature 1965; 205: 1118
   PubMedGoogle Scholar
• Albin M. S., Orr M. D., Bunegin L. B., Henderson P. A. tetrahydroaminoacridine antagonism to narcotic addiction. Exp. Neurol. 1975; 46: 644
   PubMed Web of Science ®Google Scholar
• Albin M. S., Bunegin L., Massopust L. C., Jannetta P. J. Ketamine‐induced post‐anesthetic delirium attenuated by tetrahydroaminoacridine. Exp. Neurol. 1974; 44: 126
   PubMed Web of Science ®Google Scholar
• Albin M. S., Bunegin L., Jannetta P. J., Massopust L. C. tetrahydroaminoacridine (THA) I. Effect on post‐anesthetic emergence responses and anesthesia sleep‐time after ketamine, phencyclidine, and thiamylal in animals. Excerpta Med. Int. Congr. Ser. 1974; 347: 143
   Google Scholar
• Maryani S., Weinstein H., Cohen S. Acetylcholine‐like molecular arrangement in psychotomimetic anticholinergic drugs. Proc. Natl. Acad. Sci. U.S. 1973; 70: 3103
   PubMed Web of Science ®Google Scholar
• Maryani S., Weinstein H., Ben‐Zue N., Cohen S., Sokolovsky M. Psychotomimetics as anticholinergic agents I. Cyclohexylpiperidine derivatives: Anticholinesterase activity and antagonistic activity to acetylcholine. Biochem. Pharmacol. 1974; 23: 1263
   PubMed Web of Science ®Google Scholar
• De La Lande I. S., Bentley G. The action of morphine and antagonists of the narcotic action of morphine on acetylcholine synthesis in brain. Aust. J. Exp. Biol. Med. Sci. 1955; 33: 555
   PubMedGoogle Scholar
• De La Lande I. S., Porter R. S. The actions of tacrine (THA) and aminphenazole on acetylcholine metabolism in the guinea pig ileum. Aust. J. Exp. Biol. Med. Sci. 1963; 41: 149
   PubMedGoogle Scholar
• Porter R. B. Some actions of tacrine on slow muscles of the toad (Bufo marinus) and the chick. Br. J. Pharmacol. 1965; 25: 179
   Web of Science ®Google Scholar
• Howland J. C., Carter M. K. The diuretic activity of tetrahydroaminoacridine in rats (34825). Proc. Soc. Exp. Biol. Med. 1970; 134: 513
   PubMed Web of Science ®Google Scholar
• Albert A. Improved synthesis of amino acridines. J. Soc. Chem. Ind. (Chem.) 1945; 65: 169
   Google Scholar
• Heilbronn E. Inhibition of cholinesterases by tetrahydroaminoacridine. Acta Chem. Scand. 1961; 15: 1386
   Google Scholar
• Kaul P. N. Enzyme inhibiting action of tetrahydroaminoacridine and its structural fragments. J. Pharm. Pharmacol. 1962; 14: 243
   PubMed Web of Science ®Google Scholar
• Hunter A. R. Tetrahydroaminoacridine in anesthesia. Br. J. Anaest. 1965; 37: 505
   PubMedGoogle Scholar
• Rubbo S. D. Influence of chemical constitution on toxicity. Br. J. Exp. Pathol. 1947; 28: 1
   PubMed Web of Science ®Google Scholar
• Ungar J., Robinson F. A. Investigation of antibacterial and toxic actions of certain acridine derivatives. J. Pharmacol. Exp. Ther. 1944; 80: 217
   Google Scholar
• Brodie D. E., Way E. L., Lowenhaupt E. Studies on 9‐aminoacridine antagonism of morphine and related drugs. Arch. Int. Pharmacodyn. 1952; 89: 1
   PubMedGoogle Scholar
• Cristie G., Gershon S., Gray R., Shaw F. H., McCance I., Bruce D. W. Treatment of certain side effects of morphine. Br. Med. J. 1958; 1: 675
   PubMed Web of Science ®Google Scholar
• Crankshaw T. P. A Suxamethonium Potentiator. Presented at the Second World Congress of Anaesthesiologists, Toronto. 1960
   Google Scholar
• Gordh T., Wahlin A. Potentiation of the neuromuscular effect of succinylcholine by tetrahydroaminoacridine. Acta Anaesthesiol. Scand. 1961; 5: 55
   PubMed Web of Science ®Google Scholar
• Gershon S., Shaw F. H. Tetrahydroaminoacrine as a decurarising agent. J. Pharm. Sci. 1958; 10: 638
   Google Scholar
• Hunter A. R. An appraisal of tacrine‐extended suxamethonium. Br. J. Anaesth. 1970; 42: 155
   PubMedGoogle Scholar
• Jones C. R., Davis M. Replacement drug for edrophonium bromide. Med. J. Aust. 1975; 2: 650
   PubMed Web of Science ®Google Scholar
• Albin M. S., Aguirre E. M., Albin R. L. Tetrahydroaminoacridine (THA) II. Modifications of post‐anesthetic emergence responses and anesthesia sleep‐time after ketamine hydrochloride (KH) in the human. Excerpta Med. Int. Congr. Ser. 1974; 347: 147
   Google Scholar
• Mendelson G. Central anticholinergic syndrome reversed by tetrahydroaminoacrine (THA). Med. J. Aust. 1975; 1: 906
   Google Scholar